-
Biogen Reveals $900M Settlement In Whistleblower's MS Drug Kickbacks Lawsuit Days Before Trial
Thursday, July 21, 2022 - 2:15am | 361Read More...Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlement agreement to resolve previously disclosed "qui tam" litigation related to its conduct before 2015. Qui tam is a type of whistleblower...
-
Lingo Failure Leads Citi To Downgrade Biogen
Wednesday, June 8, 2016 - 10:03am | 261Read More...Biogen Inc (NASDAQ: BIIB) announced that anti-Lingo failed both the primary and the secondary endpoints in its Phase 2 RRMS trial. Citi’s Robyn Karnauskas downgraded the rating on the company from Buy to Neutral, while lowering the price target from $345 to $295. Lingo Failure “While...
-
Mike Khouw Is Bullish On MS
Wednesday, June 16, 2010 - 6:47pm | 108Read More...Mike Khouw said on CNBC's Fast Money that he is looking at Morgan Stanley (NYSE: MS), and he is mildly bullish on this stock. Mike Khouw explained that he wants to sell the July 28 call for $0.25 and buy the July 26 call for $0.95. Additionally, he would sell the July 24 put for $0.60. This trade...
